Inventor · disambiguated record
Meina Liang
Also filed as: LIANG MEINA · LIANG MEINA L
25 granted patents·9 pending applications·389 citations·filing 1998–2023
96Inventor score
Top patents by PatentIndex Score
34 records- 0196US7202343B2Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereofABGENIX INC·Filed 2003·Granted Apr 10, 2007·78 cites·39 claims
- 0295US7285269B2Antibodies directed to tumor necrosis factorAMGEN FREMONT INC·Filed 2003·Granted Oct 23, 2007·101 cites·35 claims
- 0394US6207665B1Piperazine derivatives and their use as anti-inflammatory agentsSCHERING AG·Filed 1998·Granted Mar 27, 2001·89 cites·11 claims
- 0489US6555537B2Piperazine derivatives and their use as anti-inflammatory agentsSCHERING AG·Filed 2000·Granted Apr 29, 2003·24 cites·3 claims
- 0588US8710191B2Antibodies to CCR2GLADUE RONALD P·Filed 2009·Granted Apr 29, 2014·21 cites·11 claims
- 0688US6534509B1Piperazine derivatives and their use as anti-inflammatory agentsSCHERING AG·Filed 2000·Granted Mar 18, 2003·19 cites·4 claims
- 0787US7482434B2Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereofASTRAZENECA AB·Filed 2006·Granted Jan 27, 2009·8 cites·24 claims
- 0885US10829557B2Anti-B7-H1 antibodies for treating tumorsMEDIMMUNE LTD·Filed 2019·Granted Nov 10, 2020·2 cites·9 claims
- 0982US7220856B2Substituted quinoline CCR5 receptor antagonistsSCHERING AG·Filed 2003·Granted May 22, 2007·22 cites·8 claims
- 1081US11016099B2Prediction of clinical response to IL23-antagonists using IL23 pathway biomarkersAMGEN INC·Filed 2016·Granted May 25, 2021·3 cites·22 claims
- 1180US8846873B2Antibodies directed to GPNMB and uses thereofXIAO FENG·Filed 2012·Granted Sep 30, 2014·9 cites·27 claims
- 1277US11220541B2CCL20 as a predictor of clinical response to IL23-antagonistsAMGEN INC·Filed 2016·Granted Jan 11, 2022·1 cites·32 claims
- 1376US10336823B2Anti-B7-H1 antibodies for treating tumorsMEDIMMUNE LTD·Filed 2014·Granted Jul 2, 2019·3 cites·18 claims
- 1475US7687606B2Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereofASTRAZENECA AB·Filed 2006·Granted Mar 30, 2010·1 cites·33 claims
- 1574US8101178B2Antibodies directed to tumor necrosis factor and uses thereofBABCOOK JOHN S·Filed 2007·Granted Jan 24, 2012·3 cites·21 claims
- 1672US6541476B1Piperazine derivatives and their use as anti-inflammatory agentsSCHERING AG·Filed 2000·Granted Apr 1, 2003·3 cites·9 claims
- 1770US10775388B2Methods of using antibodies to determine periostin levels in a sampleMEDIMMUNE LLC·Filed 2015·Granted Sep 15, 2020·1 cites·23 claims
- 1870US9238691B2Nucleic acids encoding antibodies to CCR2PFIZER·Filed 2014·Granted Jan 19, 2016·1 cites·31 claims
- 1969US11827706B2Anti-B7-H1 antibodies for treating tumorsMEDIMMUNE LTD·Filed 2020·Granted Nov 28, 2023·0 cites·20 claims
- 2064US2023303707A1Anti-pad4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritisMEDIMMUNE LTD·Filed 2023·Application pending·0 cites
- 2163US2022144935A1Ccl20 as a predictor of clinical response to il23-antagonistsAMGEN INC·Filed 2021·Application pending·0 cites
- 2261US2024150469A1Anti-b7-h1 antibodies for treating tumorsMEDIMMUNE LTD·Filed 2023·Application pending·0 cites
- 2360US7268140B2Piperazine derivatives and their use as anti-inflammatory agentsSCHERING AG·Filed 2005·Granted Sep 11, 2007·0 cites·11 claims
- 2456US11613580B2Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritisMEDIMMUNE LTD·Filed 2017·Granted Mar 28, 2023·0 cites·11 claims
- 2556US6977258B2Piperazine derivatives and their use as anti-inflammatory agentsSCHERING AG·Filed 2003·Granted Dec 20, 2005·0 cites·19 claims
- 2656US6972290B2Piperazine derivatives and their use as anti-inflammatory agentsSCHERING AG·Filed 2003·Granted Dec 6, 2005·0 cites·23 claims
- 2755US9862762B2Monoclonal antibodies which bind human periostinMEDIMMUNE LLC·Filed 2015·Granted Jan 9, 2018·0 cites·18 claims
- 2855US2018179272A1Novel assay to detect human periostinMEDIMMUNE LLC·Filed 2017·Application pending·0 cites
- 2955US2015044212A1Antibodies Directed to GPNMB and Uses ThereofCELLDEX THERAPEUTICS INC·Filed 2014·Application pending·0 cites
- 3053US6573266B1Piperazine derivatives and their use as anti-inflammatory agentsSCHERING AG·Filed 2000·Granted Jun 3, 2003·0 cites·4 claims
- 3153US2022373539A1Prediction of clinical response to il23-antagonists using il23 pathway biomarkersAMGEN INC·Filed 2021·Application pending·0 cites
- 3247US2016311919A1Antibodies Directed To GPNMB And Uses ThereofCELLDEX THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 3344US2005058649A1Antibodies directed to phospholipase A2 and uses thereofFiled 2003·Application pending·0 cites
- 3431US2016363591A1Dipeptidyl peptidase-4 (dpp4/cd26) as a peripheral biomarker of il-13 activation in asthmatic lungMEDIMMUNE LLC·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →